# Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Study · id `cardio:ct-nct03798080` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03798080](<https://clinicaltrials.gov/study/NCT03798080>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03798080

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.

## Technical summary

Registry record NCT03798080. Randomized; no masking; primary purpose treatment. Start 2019-02-19 (actual); primary completion 2020-12-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 426 participants (enrolled count; ClinicalTrials.gov record NCT03798080, source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)
- Started: 2019-02-19 (actual) (ClinicalTrials.gov record NCT03798080, source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)
- Primary completion: 2020-12-01 (actual) (ClinicalTrials.gov record NCT03798080, source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)
- Completion: 2020-12-01 (actual) (ClinicalTrials.gov record NCT03798080, source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03798080, source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03798080-2022-07-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
- Acronym: Lixilan-L-CN
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug): Insulin glargine (HOE901)
- Intervention (Drug): Metformin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study (`cardio:pubmed-39360440`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fe10bf68c64b73605bb70368a51eeb19f7a00b5bfc419f355a1e3ed6d080eba2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
